5-year follow-up of phase 3 KEYNOTE-590 (749 adults, advanced oesophageal cancer): pembrolizumab plus chemotherapy vs placebo plus chemotherapy, median OS 12.3 vs 9.8 months (HR 0.72); 5-year OS 10.6% vs 3.0%; grade 3+ TRAEs 71.9% vs 67.6%.
RCTn = 749
Metges et al. Pembrolizumab plus chemotherapy versus chemotherapy for advanced esophageal cancer: 5-year extended follow-up for the randomized phase III KEYNOTE-590 study